Expanding Sales and Developing Applications for HPC and NISSO-PB
First written in FY2016. 15 of 32 entries say "Restated". Latest entry: 2026-08-07.
The whole theme swung hardest in 2020: 2 of 11 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2026RestatedAnnual report
「In chemical materials, the pharmaceutical excipient “NISSO HPC,” the resin additive “NISSO-PB” and the KrF photoresist material “VP Polymer” are expected to remain firm.」
HPC, NISSO-PB and VP Polymer are expected to remain firm as high-value-added products, with no change in the policy of expanding sales and developing applications disclosed. - FY2026-H1RestatedAnnual report
「Functional materials reported higher revenue due to an increase in the resin additive “NISSO-PB.” Pharmaceuticals and industrial fungicides also reported higher revenue due to growth in the pharmaceutical excipient “NISSO HPC” and pharmaceutical active ingredients, among other factors.」
The company continues to disclose increased sales and growth in NISSO-PB and NISSO HPC. - FY2025-H1NISSO-PB and NISSO HPC growthAnnual report
「Functional materials reported higher revenue due to growth in the resin additive “NISSO-PB.” Pharmaceuticals and industrial fungicides also reported higher revenue as growth in the pharmaceutical excipient “NISSO HPC” and other factors more than offset the decline in pharmaceutical active ingredients.」
The previous fiscal year saw a reported decline in NISSO-PB and an increase in NISSO HPC, while growth in both products was reported for the interim period. - FY2024NISSO HPC increased; VP Polymer declinedAnnual report
「Functional materials reported lower revenue due to declines in the KrF photoresist material “VP Polymer” and the resin additive “NISSO-PB.” Pharmaceuticals and industrial fungicides reported higher revenue as the increase in the pharmaceutical excipient “NISSO HPC” more than offset the decline in industrial fungicides.」
Among the high-value-added products, NISSO HPC increased, while VP Polymer and NISSO-PB declined, resulting in divergent trends by product. - FY2024-Q2NISSO-PB and VP Polymer declined; NISSO HPC remained firmAnnual report
「Functional materials reported lower revenue due to declines in the resin additive “NISSO-PB” and the KrF photoresist material “VP Polymer.” Pharmaceuticals and industrial fungicides were broadly unchanged year on year, as the firm performance of the pharmaceutical excipient “NISSO HPC” was offset by a decline in industrial fungicides and other factors.」
Among the high-value-added products, NISSO-PB and VP Polymer declined, while NISSO HPC remained firm. - FY2023-Q3RestatedAnnual report
「Although sales of industrial chemicals and Eco Care products declined following structural reforms in the caustic potash and related businesses, growth in the pharmaceutical excipient “NISSO HPC,” the KrF photoresist material “VP Polymer” and secondary battery materials, together with revisions to selling prices in response to the substantial increase in raw material and fuel prices, resulted in revenue of ¥34.742 billion for the cumulative period, up 15.1% year on year.」
High-value-added products, including NISSO HPC, VP Polymer and secondary battery materials, grew and contributed to higher revenue in the chemicals business. - FY2023-Q2RestatedAnnual report
「Pharmaceuticals and industrial fungicides reported higher revenue due to growth in the pharmaceutical excipient “NISSO HPC” and pharmaceutical active ingredients.」
The company continues to disclose growth in NISSO HPC, previously identified as a growth product, and its contribution to higher revenue. No change in its policy of expanding sales and developing applications has been indicated. - FY2022-Q3RestatedAnnual report
「Revenue for the cumulative period was ¥30.184 billion, up 12.6% year on year, due mainly to increases in secondary battery materials, the pharmaceutical excipient “NISSO HPC” and the resin additive “NISSO-PB,” as well as solid performance by the consolidated subsidiary Alkaline SAS.」
NISSO HPC and NISSO-PB, previously identified as growth products, increased and contributed to higher revenue in the chemicals business. - FY2022-Q2RestatedAnnual report
「Functional materials reported higher revenue due to increases in the resin additive “NISSO-PB” and the KrF photoresist material “VP Polymer.” Pharmaceuticals and industrial fungicides were broadly unchanged year on year, as the increase in the pharmaceutical excipient “NISSO HPC” was offset by a decline in pharmaceutical active ingredients.」
The company reported increased sales of NISSO-PB and NISSO HPC, continuing the trend of expanding sales and increasing the value added of both products. - FY2022-Q1AdvancedAnnual report
「Construction in progress decreased by ¥5.13 billion following the start of operations at expanded production facilities for the pharmaceutical excipient “NISSO HPC.” Machinery and equipment increased by ¥3.03 billion, while buildings and structures increased by ¥2.142 billion.」
The expansion facilities for NISSO HPC began operations, marking concrete progress in capital investment. - FY2021NISSO HPC growth continuesAnnual report
「Pharmaceuticals and industrial fungicides reported lower revenue as declines in pharmaceutical active ingredients and industrial fungicides more than offset growth in the pharmaceutical excipient “NISSO HPC.”」
NISSO HPC, previously identified as a growth product, continued to grow in the fiscal year, but pharmaceuticals and industrial fungicides reported lower revenue due to declines in related fields. - FY2021-Q3NISSO HPC sales increase continuesAnnual report
「Although the pharmaceutical excipient “NISSO HPC” increased, revenue for the cumulative period was ¥26.809 billion, down 11.0% year on year, due mainly to declines in industrial chemicals and chemical products.」
The increase in NISSO HPC was again reported, following the second quarter. Meanwhile, revenue for the chemicals business as a whole declined 11.0% year on year. - FY2021-Q1NISSO HPC sales increasedAnnual report
「Although the pharmaceutical excipient “NISSO HPC” increased, revenue for the cumulative period was ¥9.154 billion, down 12.5% year on year, due mainly to declines in industrial chemicals and chemical products.」
NISSO HPC had been described as firm for the previous full year, but sales increased in the first quarter. Meanwhile, revenue for the chemicals business as a whole declined 12.5% year on year. - FY2020NISSO HPC remained firm; NISSO-PB declinedAnnual report
「Functional materials reported lower revenue due to declines in the KrF photoresist material “VP Polymer” and the resin additive “NISSO-PB.” Pharmaceuticals and industrial fungicides reported higher revenue as the pharmaceutical excipient “NISSO HPC” and pharmaceutical raw materials remained firm.」
The previous filing reported an increase in NISSO-PB, but it turned to a decline for the full year. Meanwhile, NISSO HPC remained firm and contributed to higher revenue. - FY2020-Q2Decline in NISSO HPC; increase in NISSO-PBAnnual report
「Pharmaceuticals and industrial fungicides reported lower revenue due to declines in the pharmaceutical excipient “NISSO HPC” and industrial fungicides. Functional materials reported higher revenue as the increase in the resin additive “NISSO-PB” more than offset the decline in the KrF photoresist material “VP Polymer.”」
Although sales of NISSO HPC continued to decline, NISSO-PB increased and contributed to higher revenue in functional materials. - FY2020-Q1Decline in NISSO HPC salesAnnual report
「Although sales of the pharmaceutical excipient NISSO HPC declined, sales for the cumulative period amounted to ¥10.463 billion, up 1.6% year on year, due mainly to the launch of sales of secondary-battery materials and steady performance by the polymer additive NISSO-PB.」
NISSO HPC, previously treated as a growth product, saw lower sales in the first quarter. NISSO-PB, however, performed steadily, while the launch of secondary-battery materials was also cited as a factor behind higher Chemicals Business revenue. - FY2019RestatedAnnual report
「Although the KrF photoresist material VP Polymer and polymer additive NISSO-PB performed steadily, Functional Materials revenue was broadly unchanged from the previous year due mainly to declines in materials for the IT industry.」
NISSO-PB continues to perform steadily, and no change is mentioned in the policy of expanding sales of high-value-added products such as HPC and NISSO-PB. - FY2019-Q3RestatedAnnual report
「Sales for the cumulative period amounted to ¥31.326 billion, up 6.3% year on year, due to steady performance by caustic soda, thermal-paper developers and the pharmaceutical excipient NISSO HPC.」
NISSO HPC, previously regarded as a growth driver, continued to perform steadily during the cumulative third-quarter period and contributed to higher Chemicals Business revenue. - FY2019-Q2RestatedAnnual report
「Revenue from pharmaceuticals and industrial biocides increased due to growth in the pharmaceutical excipient NISSO HPC.」
NISSO HPC, previously regarded as a growth driver, also grew during the cumulative second-quarter period and contributed to higher revenue. - FY2019-Q1RestatedAnnual report
「Sales for the cumulative period amounted to ¥10.299 billion, up 6.1% year on year, due to steady performance by caustic soda and the pharmaceutical excipient NISSO HPC.」
NISSO HPC, previously regarded as a growth driver, also performed steadily in the first quarter and contributed to higher Chemicals Business revenue. - FY2018RestatedAnnual report
「Revenue from pharmaceuticals and pharmaceutical intermediates increased due to growth in the pharmaceutical excipient NISSO HPC.」
For HPC, which has been regarded as a growth driver, the document also reports higher full-year revenue due to sales growth. - FY2018-Q3Growth in HPC salesAnnual report
「Although sales of thermal-paper developers and the heavy-metal immobilizer Hygion declined, sales for the cumulative period amounted to ¥29.479 billion, up 8.3% year on year, due mainly to growth in sodium metal and the pharmaceutical excipient HPC.」
HPC, previously identified as a target of the expanded-sales and application-development strategy, is reported to have grown during the cumulative third-quarter period. - FY2017Continued decline in NISSO-PB salesAnnual report
「In the Chemicals Business, the Company expects demand and market conditions for industrial chemicals to recover, as well as progress in expanded sales and application development in the cellulose derivatives and functional polymers businesses.」
The cellulose derivatives and functional polymers businesses were identified as targets for expanded sales and application development, while actual results showed declines in products such as the polymer additive NISSO-PB. - FY2017-Q3Decline in NISSO-PB salesAnnual report
「Although caustic potash and other products performed steadily, sales for the cumulative period amounted to ¥27.226 billion, down 14.1% year on year, due mainly to declines in sodium cyanide, the polymer additive NISSO-PB and other products, as well as the discontinuation of sales of certain pharmaceutical ingredients.」
No change in the policy of expanding sales and developing applications for HPC and NISSO-PB is mentioned, but NISSO-PB, previously described as performing steadily, is reported to have declined during the cumulative third-quarter period. - FY2017-Q1RestatedAnnual report
「Although NISSO-PB, a polymer additive, and HPC, a pharmaceutical excipient, performed steadily, sales in the Chemicals Business for the cumulative period amounted to ¥9.463 billion, down 12.3% year on year, due mainly to declines in sodium cyanide, thermal-paper developers and other products, as well as the discontinuation of sales of certain pharmaceutical ingredients.」
Although HPC and NISSO-PB continued to perform steadily, total sales in the Chemicals Business declined 12.3% year on year, and no change in the policy of expanding sales and developing applications is indicated. - FY2016First statedAnnual report
「The Company expects sales to increase through expanded sales and progress in application development for HPC, a pharmaceutical excipient, and NISSO-PB, a polymer additive, which it regards as growth drivers.」
The Company regards HPC and NISSO-PB as growth drivers and identifies expanded sales and application development as means of increasing sales.